In this clinical trial the effect of phenelzine treatment on a number of mesenchymal markers including CSV, EGFR, FOXQ1, SNAI1 and PD-L1 were assessed using patient derived circulating tumor cells (CTCs) from liquid biopsies taken at baseline and at 29, 57 and 85 days post start of phenelzine therapy. Here, SNAI1 is linked to neoplasm.